FYB1 (FYN binding protein 1) is an adapter protein that functions as a critical signaling node in immune cells. It acts downstream of the FYN and LCP2 signaling cascades in T cells 1, linking T-cell receptor (TCR) signaling to actin cytoskeleton remodeling 23. FYB1 is recruited into SLP-76 microclusters following TCR ligation and facilitates integrin activation via interactions with talin-1 and kindlin-3 1. The protein stabilizes SKAP1 and SKAP2, preventing their degradation 4, and plays roles in platelet activation and mast cell signaling. FYB1 has emerged as a disease biomarker across multiple pathologies. In T-cell acute lymphoblastic leukemia (T-ALL), FYB1 is overexpressed as an super enhancer-driven gene and promotes leukemic cell self-renewal by activating IGLL1; FYB1 knockdown suppresses tumor growth and improves survival 5. In multiple sclerosis, a 11-protein CSF signature including FYB1 predicts disability severity with high accuracy (AUC=0.90) 6. FYB1 is upregulated in mycosis fungoides (cutaneous T-cell lymphoma) relative to psoriasis and chr5 spongiotic dermatitis, serving as a diagnostic biomarker with 73.2% sensitivity and 69.2% specificity 7. Additionally, FYB1 is implicated in inherited thrombocytopenia-3 and appears dysregulated in obesity and periodontitis where it associates with macrophage activity and inflammatory responses 8. These findings position FYB1 as both a fundamental regulator of immune cell function and a promising therapeutic target.